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Abstract 
Background: In eukaryotes, the serpins constitute a wide family of protease inhibitors regulating many physiologi-
cal pathways. Many reports stressed the key role of serpins in several human physiopathologies including mainly the 
inflammatory bowel diseases. In this context, eukaryotic serpins were largely studied and their use to limit inflam-
mation was reported. In comparison to that, bacterial serpins and mainly those from human gut microbiota remain 
poorly studied.
Results: The two genes encoding for putative serpins from the human gut bacterium Eubacterium sireaum, display 
low sequence identities. These genes were overexpressed and the encoded proteins, named Siropins, were purified. 
Activity studies demonstrated that both purified proteins inhibited serine proteases but surprisingly they preferen-
tially inhibited two human serine proteases (Human Neutrophil Elastase and Proteinase3). The biochemical characteri-
zation of these Siropins revealed that Siropin 1 was the most active and stable at low pH values while Siropin 2 was 
more thermoactive and thermostable. Kinetic analysis allowed the determination of the stoichiometry of inhibition 
(SI) which was around 1 and of the association rate constants of 7.7 × 104 for the Human Neutrophil Elastase and 
2.6 × 105 for the Proteinase3. Moreover, both Siropins displayed the ability to inhibit proteases usually present in fecal 
waters. Altogether our data indicate the high efficiency of Siropins and their probable involvement in the control of 
the overall intestine protease activity.
Conclusions: Here we report the purification and the biochemical characterization of two novel serpins originated 
from Eubacterium sireaum, a human gastro-intestinal tract commensal bacteria. These proteins that we called Siropins, 
efficiently inhibited two human proteases reported to be associated with inflammatory bowel diseases. The deter-
mination of the biochemical properties of these enzymes revealed different temperature and pH behaviours that 
may reflect adaptation of this human commensal bacterium to different ecological environments. To the best of our 
knowledge, it is the first bacterial serpins showing an attractive inhibition of fecal proteases recovered from a mice 
group with chemically induced inflammation. Altogether our data highlight the interesting potential of Siropins, and 
serpins from the human gut microbiota in general, to be used as new alternative to face inflammatory diseases.
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Background
The serine protease inhibitors (serpins) represent 
the most widely distributed superfamily of protease 
inhibitors having been identified across all branches of 
life including eukaryotes as well as viruses and prokar-
yotes [1, 2]. Serpins are being extensively studied in 
humans and they have been reported to inhibit proteo-
lytic activities involved in many physiological processes 
including: inflammatory responses, blood coagulation 
and fibrinolysis [3, 4]. The viral serpins are associated to 
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virulence through the inactivation of the proteases of the 
host immune system [5, 6]. Moreover, serpins also oper-
ate through non inhibitory mechanisms on many physi-
ological functions such as tumor suppression, molecular 
chaperone activity, chromatin compaction and hormone 
transport [1]. Unlike small protease inhibitors acting by 
a reversible way, serpins are distinguishable by their irre-
versible suicide mechanism of inhibition [7]. Indeed, the 
serpin inhibition activity is associated to the Reactive 
Center Loop (RCL) which interacts with target protease 
thereby resulting in the cleavage of the RCL that enables 
the establishment of a covalent acyl-enzyme complex. 
These main structural reshuffles will induce an important 
distortion of the protease leading to its inactivation [8].
Comparatively to the knowledge on the eukaryotic ser-
pins function, that regarding the bacterial serpins is still 
very limited [1]. In fact, until now only few microbial 
serpins were reported including those from Clostridium 
thermocellum, Tannerella forsythia, Thermobifida fusca 
and Thermoanaerobacter tengcondensis [9–13]. While 
these bacterial serpins were characterized, their physi-
ological roles are still to be investigated.
Interestingly, only one serpin from the human com-
mensal bacterium Bifidobacterium longum NCC2705 
strain was studied. In fact, it was demonstrated that this 
bacterial serpin inhibited several eukaryotic serine pro-
teases and mainly the Human Neutrophil Elastase (HNE) 
[14]. Taking into account that eukaryotic serine proteases 
are associated with several human protease-mediated 
physiopathologies and essentially inflammatory bowel 
diseases (IBD), the serpins can constitute a promising 
therapeutic approach to treat such diseases [14]. This 
claim is strengthened by the demonstration that the 
human specific inhibitor of HNE (Elafin) allowed the 
reduction of induced digestive inflammation in a rodent 
model [15]. In this framework, the interest towards the 
bacterial serpins from the human gut microbiota is tak-
ing more importance when one considers the higher 
numbers of these polypeptides compared to the 36 ser-
pins encoded by the human body [1]. The recent scien-
tific breakthroughs in the gut microbiota studies clearly 
demonstrated the association between the gut microbi-
ota and IBD [16, 17]. Consequently, the serpins encoded 
by the human gut microbiota today appear as attractive 
candidates to counteract the deleterious damages asso-
ciated with the GIT-derived protease activities and may 
ensure an important competitive advantage to survive in 
this ecological context [14, 18]. Therefore, serpins from 
the gut microbiota may have therapeutic potential which 
remains hitherto unexplored.
Here we report the cloning, over-expression, purifica-
tion and biochemical characterization of two novel ser-
pins isolated from the human commensal Eubacterium 
sireaum. The purified serpins were characterized. They 
display differential inhibitor efficiency against human 
serine proteases. Interestingly, these proteins constitute 
the first bacterial serpins inhibiting the human Protein-
ase3 and the fecal proteases from inflamed mice.
Results and discussion
Genes in silico analysis, cloning and over‑expression
Analysis of the amino-acid sequence multiple alignment 
demonstrates that Siropin 1 and 2 have 60% of identity. 
Sequence inspection of the Siropin 1 and 2 with other 
serpins reveals that they display sequence identities of 
only 19 and 20% with the previously studied serpin from 
the gut bacterium B. longum (Fig.  1). The same study 
revealed that the serpins from Tannerella forsythia and 
Thermobifida fusca displayed low identities of 23 and 24% 
with the Siropin 1 and of 21 and 19% with Siropin 2. By 
using TMHMM and SignalP programs we conclude that 
Siropin 1 is an intracellular protein; but Siropin 2 was 
significantly predicted as an extracellular protein (data 
not shown). The sequence identity of the two Siropins 
increased to 63% when the presumed signal sequence 
was omitted from Siropin 2. In addition, the alignment 
of the RCL sequences from Siropins displays an identity 
value of only 48%. These low sequence identities can be 
explained by what was previously suggested concerning 
the serpin genes in prokaryotes i.e., that they are most 
probably prone to horizontal gene transfer [2, 19].
As shown in Fig.  1, both Siropins possess three β 
sheets, eight α helices and an exposed RCL which are the 
structural elements that characterize all members of ser-
pin family [2, 20]. Moreover, analysis of the RCL region 
demonstrates that the Siropins hinge sequences are 
mainly composed by small and highly conserved amino 
acids including Glycine and Alanine (Fig. 1). This obser-
vation suggests that the two proteins studied herein most 
probably act as proteases inhibitors [2, 21].
To investigate this hypothesis, two DNA fragments of 
approximately 1.5  kb were amplified using Eubacterium 
siraeum chromosomal DNA as template and two oligo-
nucleotides designed for each gene. These DNA frag-
ments were cloned under control of the T7 promoter and 
in frame with six histidine residues at the N-terminal side 
of the encoded proteins. For both Siropins, structural 
model showed that the N-termini are located away from 
the active sites (Additional file 1: Fig. S1). The calculated 
molecular weights were 43.75 and 48.1  kDa for Siropin 
1 and Siropin 2, respectively. After transformation into 
E. coli BL21 (DE3), numerous colonies were observed 
and subsequently analyzed by PCR and DNA sequencing. 
Monitoring of the liquid culture of each selected clone 
followed by western blotting using the intracellular crude 
extract, showed the presence of bands with a molecular 
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Fig. 1 Multiple sequence alignment of Siropin 1 and 2 with Thermopin (Uniprot accession number Q47NK3R), Miropin (Uniprot accession number 
G8UQY8), human α-1-antitrypsin (UniProt accession number P01009), B. longum serpin (UniProt accession number Q8G7X7) and Tengpin (UniProt 
accession number Q8R9P5). The structural elements shown above the alignment were generated using the native α-1-antitrypsin structure (PDB 
ID: 1QLP) sequence invariant residues between sequences are typed red on a white background and residues conserved within each group are 
displayed as white letters on a red background. Underlined sequences represent the predicted hinge region (blue) and reactive center loop (yellow). 
The predicted cleavage site is marked with a double vertical line. P1 and P1′ residues are labeled
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weight of nearly 44 and 46 kDa close to the theoretically 
expected one (Fig.  2b, d). These results were confirmed 
by mass spectrometry analysis which proved the cor-
respondence of these protein species to Siropin 1 and 2 
(data not shown). These data demonstrate the molecular 
cloning and the expression of the E. siraeum serpin genes 
in E. coli BL21.
Purification of Siropins, spectrum and stoichiometry 
of inhibition
After an overnight liquid cell cultures of the recombinant 
E. coli BL21 strains over-expressing both serpins, the 
protein crude extracts were subjected to an affinity chro-
matography step. High purity enzyme preparations were 
obtained with size exclusion chromatographies which 
displayed single elution peaks with apparent molecular 
masses of 45 kDa and 50 kDa for Siropin 1 and 2, respec-
tively (Fig. 1e). The electrophoresis under reducing con-
ditions and mass spectrometry analysis revealed the 
presence of homogenous single bands with molecular 
masses of around 44 and 46 kDa (Fig. 2a, c, f and g), sug-
gesting that both serpins from E. siraeum have a mono-
meric arrangement. Such organization is similar to those 
adopted by serpins from Thermococcus kodakaraensis, 
Tannerella forsythia, Pyrobaculum aerophilum and Ther-
mobifida fusca [10, 12, 22, 23].
Interestingly, purification yields were about 12 mg and 
8  mg of protein per liter of culture for Siropin 1 and 2, 
respectively. In comparison, previously reported purifica-
tion yields per liter were 25 µg, 3 and 10 mg for serpins 
from Tannerella forsythia, Thermococcus kodakaraen-
sis and Bifidobacterium longum [10, 14, 22]. Altogether 
Fig. 2 Electrophoretic, size exclusion chromatography and mass spectrometry analysis of the purified Siropins. a and c SDS-PAGE of purified Siropin 
1 and Siropin 2, respectively. b and d Western blot detection of purified Siropin 1 and Siropin 2, respectively. Lane M protein marker (molecular mass 
in kilodaltons); lane 1 and 2 purified Siropin 1; lane 3 and 4 purified Siropin 2. e Size exclusion chromatography analysis of the purified recombinant 
proteins shows a single peak of 50 kDa for Siropin 2 (RT 15 min, continue line) and 45 kDa for Siropin 1 (RT 15.5 min, dashed line) using protein mark-
ers of 669 kDa (TR 8.9 min), 440 kDa (TR 11.3 min), 158 kDa (TR 13.2 min), 75 kDa (TR 14.1 min), 44 kDa (TR 15.3 min) and 29 kDa (TR 16.9 min). f and 
g Mass spectrometry analysis of the Siropin 1 and Siropin 2, respectively
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these data indicate that the Siropin 1 and 2 are well 
expressed in E. coli and that the used purification proce-
dure allowed the achievement of high yields of serpins. 
The obtained pure protein amounts were sufficient for 
the investigation of the inhibition spectrum of Siropins. 
As shown in Fig.  3a, none of the Siropins inhibited the 
pancreatic porcine elastase (PPE), bovine pancreatic 
trypsin (BPT) and chymotrypsin (BPC). The same result 
was also observed when using subtilisin (Sub), the bac-
terial serine protease from Bacillus subtilis. In contrast, 
Siropin 1 and 2 efficiently inhibited two human serine 
proteases: the Human Neutrophil elastase (HNE) and the 
Proteinase3 (PR3). It is noteworthy that with previously 
reported serine proteases even at 10 or 20 fold higher 
molar concentrations, no inhibition was observed.
In the case of HNE and PR3 the inhibition level was 
dependent upon Siropins concentration; it allowed us 
to determine the stoichiometry of inhibition (SI). Fig-
ure  3b, c revealed that Siropin 1 has SI values of 1.76 
and 1.1 for HNE and PR3, respectively. Siropin 2 shows 
SIs of 1.82 for HNE and 1.1 for PR3 (Fig.  3b, c). SI val-
ues of Siropins with HNE are lower than that of serpin 
from Tannerella forsythia (SI = 3.4) and similar to those 
of serpins from B. longum, T. tengcondensis and of the 
human α-1-antitrypsin [13, 14, 24]. Concerning the PR3, 
the SIs of Siropins were similar to that of the human α-1-
antitrypsin [25]. Furthermore as far as we know, Siropins 
constitute the first bacterial serpins inhibiting the human 
PR3. It is well recognized that serpins allow the defense 
of bacteria through the inhibition of proteolytic activities 
contributing thus to their adaptation towards ecological 
environment. At least, it was reported that the serpins 
from Bacillus brevis and Bifidobacterium breve protected 
these bacteria from exogenous attacks through the inhi-
bition of proteases [18, 26]. In the case of E. sireaum, our 
data reavealed that it can use its Siropins to ensure a pro-
tection against the host proteases, HNE and PR3. Similar 
behavior was previously described in case of the ecotin 
from E. coli [27].
Above all it appeared that Siropins act efficiently 
against human proteases while they were not active 
against the B. subtilis subtilisin. This feature takes more 
importance when one considers that (i) HNE and PR3 
are highly over-expressed in subjects suffering from 
inflammatory bowel diseases (IBD) when compared to 
healthy one [15, 28, 29] and (ii) many reports stressed the 
involvement of serine proteases on human inflammatory 
physiopathology’s and mainly HNE and PR3 [15, 28, 29].
Identification of the RCL cleavage sites
In order to determine the P1–P1′ cleavage site in the 
RCL of Siropins, the purified proteins were incubated 
with target proteases and subsequently analyzed by SDS-
PAGE and mass spectrometry (Fig.  4). In the case of 
Siropins, the complex band was not detectable by SDS-
PAGE analysis. This kind of complex instability has been 
previously reported with other inhibitory serpins and 
it is assumed that it results from a nucleophile or water 
attack that can occur upon the complex formation lead-
ing to the release of cleaved serpin and distorted protease 
[30]. In both case (HNE and PR3) the intensity of the 
Fig. 3 Spectrum and stoichiometry of inhibition of purified Siropins. 
a Effect of Siropin1 and 2 on HNE human neutropil elastase, PR3 
proteinase 3, PPE porcine pancreatic elastase, BPT bovine pancreatic 
trypsine, BPC bovine pancreatic chymotrypsine and Sub subtilisine. 
The activity of each protease was assayed alone (green), pre-incu-
bated with Siropin 1 (blue) or with siropin 2 (red). Measured protease 
activities without serpins were defined as 100%. Error bars represent 
the standard deviation from three independent experiments. b and 
c Stoichiometry of inhibition of Siropins. Fractional protease activity 
of HNE (b) and PR3 (c) was plotted after incubation with various 
amounts of Siropin 1 (Dashed, _o_) or Siropin 2 (Continuous, _∆_)
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band corresponding to untreated serpin (44 for Siropin 
1 and 46  kDa for Siropin 2) decreased, while a slightly 
lower band appear upon addition of the target protease 
(Fig.  4a). Further mass spectrometry analyses were per-
formed on the digestion band and obtained results 
revealed that this band correspond to the RCL-cleaved 
Siropins (data not shown). Subsequently, based on the 
sequence analysis of this cleaved form, we successfully 
determined the Siropins cleavage sites which correspond 
to P3-P2 (Val338-Met339) peptide bonds for Siropin 1 
and P6-P5 (Val375-Glu376) bond for Siropin 2 both for 
HNE and PR3 (Fig. 4b). Interestingly, those cleavage sites 
are consistent with the specificity of HNE and PR3 for 
Val or Ala at P1 position.
Effects of temperature and pH on Siropins activity 
and stability
The analysis of the inhibition patterns at different tem-
peratures demonstrated that Siropin 2 was fully active 
at temperatures until 50  °C (Fig.  5a). The same study 
established that Siropin 1 was fully active up to 40 °C and 
displayed a relative inhibition of 88% at 50  °C. Amaz-
ingly, at 60  °C Siropin 2 preserves more than 90% of its 
activity whereas Siropin 1 kept less than 10% of its activ-
ity. At temperatures above 60  °C, Siropin 2 retained 
30-35% of its initial activity but Siropin 1 was almost 
inactive (Fig. 5a). Therefore, we conclude that both Siro-
pins are highly active at low temperatures, while at high 
temperatures the Siropin 2 is more thermoactive than 
Siropin 1. In comparison the previously described bacte-
rial serpin from a marine uncultured microorganism and 
Thermococcus kodakaraensis displayed optimal inhibi-
tions of 25 and 100 °C, respectively [22, 31].
Study of pH effect on Siropins revealed that these pro-
teins were highly active at pH 7.0 (Fig.  5b). Moreover, 
they retained more than 75% of their activities from pH 
6.0 to 10. Remarkably, Siropin 1 displayed higher relative 
activities at pH values ranged between 2.0 and 5.0. For 
example at pH 3.0, the relative activities of Siropin 1 and 
Siropin 2 were 60 and 10% respectively. Under high pH 
values, Siropin 1 also kept a higher relative activity than 
Siropin 2 e.g., at pH 10 Siropin 1 and 2 preserved 97 and 
80% of their relative activities, respectively.
Previous studies of the serpin deriving from a marine 
uncultured microorganism showed an optimal pH range 
of 7.0 to 8.0 and an optimal pH of 7.0 for the serpin iso-
lated from Haemonchus contortus [31, 32].
Our results established that Siropin 2 is distinguishable 
from Siropin 1 by its tolerance to high temperatures while 
Siropin 1 was active at extreme pH values compared to 
Siropin 2. In the other hand, both Siropins are highly 
active at wide range of temperature (4.0–50  °C) and pH 
(6.0–10) indicating a certain versatility of these proteins 
compatible with the gastrointestinal environment.
The thermostability studies showed that Siropin 1 
was fully stable at temperatures until 55  °C whereas at 
Fig. 4 Determination of the RCL cleavage sites of the Siropin 1 and 2 using mass spectrometry analysis. a The stained protein bands labelled with 
frames were excised and subjected to mass spectrometry analysis. Siropin 1: M protein marker; 1 Siropin 1; 2 HNE; 3 Siropin 1 + HNE; 4 PR3; 5 Siropin 
1 + PR3. Siropin 2: M protein marker; 1 Siropin 2; 2 HNE; 3 Siropin 2 + HNE; 4 PR3; 5 Siropin 2 + PR3. b Diagram of the reactive center loops showing 
the cleavage sites for each Siropin identified with HNE and PR3
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above temperatures its thermostability dropped rapidly: 
at 60  °C the enzyme’s half-life time was 10 ± 1 min. By 
contrast, Siropin 2 was fully stable upto 60  °C, and at 
70  °C, its half-live was 21  ±  0.5  min while it was only 
3 ± 0.5 min for Siropin 1 (Table 1). At higher tempera-
tures including 80 and 90  °C the Siropin 1 was inactive 
but the Siropin 2 still displayed half-lives of 20 ± 2.0 min 
and 19  ±  0.5  min, respectively (Table  1). These results 
highlighted again not only the stronger thermoactiv-
ity but also the higher thermostability of Siropin 2 com-
pared to Siropin 1. In previous reports, the serpins from 
the thermophilic Clostridium thermocellum and Ther-
mobifida fusca displayed half-lives of 30 min at 70 °C and 
28 min at 60 °C, respectively [9, 12].
Study of the pH stability revealed that both Siropins 
were highly stable at pH 7.0 and 8.0 during 8  h. At pH 
6.0 the Siropin 1 was completely stable after 8 h; yet Siro-
pin 2 displays half-live of 2.6  h. The same behavior was 
observed at higher pH values thus underlying the better 
pH stability of Siropin 1 compared to Siropin 2 (Table 2).
These different thermal and pH stability behaviors of 
Siropin 1 and 2 can be related to their low amino-acid 
sequence identity (63%). Studies on structure–function 
relationships of these bacterial serpin, mainly through 
the determination of the 3D structure of these proteins, 
will provide further structural explanations.
The different Siropins behaviors in terms of pH and 
temperature activities and stabilities can be related to the 
adaptation of this commensal bacterium E. siraeum to 
different ecological niches such as the stomach (acid pH) 
and the bowels (neutral pH).
Kinetic studies
As previously reported serpins inhibit proteases through 
an irreversible mechanism, therefore the main kinetic 
parameter which characterizes their inhibition effi-
ciencies is the association rate constant (ka). For both 
target proteases studied herein the second-order asso-
ciation rate constants were calculated by progress curve 
analysis (Fig. 6). Using the Siropin 1, the ka values were 
8.4 ± 0.07 × 104 M−1 s−1 and 2.6 ± 0.02 × 105 M−1 s−1 
for HNE and PR3, respectively. In case of Siropin 2 we 
obtained ka of 7.7  ±  0.02  ×  104 M−1 s−1 for HNE and 
of 1.1 ±  0.04 ×  105 M−1 s−1 for PR3. These data prove 
that Siropins are more efficient with PR3 than with 
HNE. The analysis of ka values of previously reported 
serpins towards HNE shows that serpins from bacterial 
origin displayed comparable values to those of Siropins 
(Table 3). In comparison, the eukaryotic α-1-antitrypsin 
and Elafin were more efficient with ka values of 6.5 107 
and 3.7 × 106 M−1 s−1, respectively (Table 3). This higher 
efficiency can be explained by the fact that both α-1-
antitrypsin and Elafin are the natural human inhibitor of 
HNE. Such statement is reinforced with the observation 
that the α-1-antitrypsin and Elafin also inhibited bet-
ter the human serine protease PR3 than Siropin 1 and 2. 
However, we report for the first time the fact that bacte-
rial serpins can inhibit the human PR3. Previous studies 
showed that to ensure the control of target proteases in 
blood plasma, serpins with less than 100  ms inhibition 
life-time are required [35]. Taken together our findings, it 
Fig. 5 Effect of temperature (a) and pH (b) on the inhibitory effect 
of the purified Siropin 1 (dashed line) and Siropin 2 (continuous line). 
Inhibitions at the optimal pH and the optimal temperature were 
defined as 100%. Error bars represent the standard deviation from 
three independent experiments
Table 1 Study of the thermal stability of Siropins
Results are the mean and standard deviation from three independent 
experiments
ND not detected





Siropin 1 10 ± 1.0 3.0 ± 0.5 ND ND
Siropin 2 >120 21 ± 1.5 20 ± 2.0 19 ± 0.5
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can be assumed that Siropins could perform an effective 
protease inhibition in the gastro-intestinal tract.
Siropins inhibit mice fecal proteases
To check the ability of Siropins to inhibit proteases 
associated with intestinal inflammation, feces were 
recovered from two conventional mice groups: the first 
group was treated with PBS while in the second group 
inflammation was induced with Dextran sulfate sodium 
(DSS, 3%). The measure of the total fecal protease activ-
ity (FPA) demonstrated that FPA in DSS-treated mice 
group was nearly 2.2 fold higher than that of the PBS-
treated group (Fig.  7a). Such results are in accordance 
with those reported in case of the human IBD patients 
Table 2 Study of the thermal pH stability of Siropins
Results are the mean and standard deviation from three independent experiments





Siropin 1 210 ± 5.0 >480 >480 >480 >480 315 ± 3.0
Siropin 2 18 ± 2.0 160 ± 1.0 >480 >480 230 ± 3.0 114 ± 2.0
Fig. 6 Progress curves for proteases inhibition by Siropins. a and c HNE inhibition by Siropin 1 (a) and Siropin 2 (c). b and d PR3 inhibition by Siropin 
1 (b) and Siropin 2 (d). Constant concentrations of HNE or PR3 were used with various amount of Siropin, the change in the absorbance was then 
performed at 37 °C. Used concentration of Siropin (µM) are shown beside each progress curve. Obtained kobs rate were plotted against the Siropin 
concentration. The apparent second-order association constant k’app was calculated as the slope of the fitted linear curve and then corrected to 
determine the second-order association constant ka
Table 3 Association rate constant values of  previously 
reported serpins
NR not reported
Results are the mean and standard deviation from three independent 
experiments
HNE PR3 Reference
Siropin 1 8.4 ± 0.07 × 104 2.6 ± 0.02 × 105 This study
Siropin 2 7.7 ± 0.02 × 104 1.1 ± 0.04 × 105 This study
α-anti-trypsin 6.5 ± 4.0 × 107 1.0 ± 0.2 × 106 [25, 33]
Elafin 3.7 ± 0.1 × 106 3.3 ± 0.03 × 106 [34]
Tengpin 1.3 × 105 NR [13]
Miropin 1.2 ± 0.05 × 105 NR [10]
Serpin from B. longum 4.7 × 104 NR [14]
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who displayed an increase of the FPA compared to that 
of healthy subjects [36, 37]. Hence our results confirmed 
again the involvement of proteases on the inflammatory 
bowel diseases. Several reports underlined the key role 
of elastolytic activity in inflammatory bowel diseases [15, 
28, 29]. As shown in Fig. 7b, the level of measured elasto-
lytic activity in mice treated with DSS was nearly fivefold 
higher than that of the PBS-treated mice group proving 
that the DSS treatment induced an increase of the pro-
tease level, and notably the elastolytic activity.
The analysis of the FPA in the presence of Siropins 
showed a significant decrease of the total proteolytic 
activity which was evaluated to 30 and 35% with Siro-
pin 1 and 2, respectively (Fig. 7a). Interestingly when the 
Siropins were added, the elastolytic activity was reduced 
to 50% with Siropin 1 and to 46% with Siropin 2. Alto-
gether these data establish that the addition of Siropins 
allowed the decrease of the FPA activity in fecal water of 
DSS-inflamed mice with a pronounced effect on the elas-
tolytic activities indicating that Siropins are highly active 
in such conditions.
These data highlighted the efficiency of the Siropins 
to inhibit fecal water proteases and thus their poten-
tial as good candidates to inhibit proteases associated 
with inflammation. Henceforth Siropins can constitute 
a promising therapeutic strategy to treat inflammatory 
diseases.
Conclusions
The human gut bacterium E. sireaum encoded two 
putative serpins which display low sequence identity 
together and with other bacterial serpins. Activity stud-
ies of these putative serpins demonstrated that they act 
as a serine protease inhibitors. The analysis of these novel 
bacterial serpins, called Siropins, revealed that they effi-
ciently inhibit the human serine proteases HNE and PR3. 
Interestingly, Siropins are the first bacterial serpins that 
significantly inhibit the human PR3. The biochemical 
characterization of both Siropins indicated that Siropin 
1 was the most active and stable at low pH values while 
Siropin 2 was more thermoactive and thermostable. 
These different behaviors can be associated to the adapta-
tion of the commensal bacterium to different ecological 
niches. Kinetic studies demonstrated that Siropins were 
highly efficient in comparison to other bacterial serpins 
including that of B. longum conferring thus to Siropins an 
interesting potential to inhibit serine proteases and spe-
cifically those associated to several human physiopathol-
ogies. To assess this hypothesis we tested the impact of 
Siropins on the proteases fecal activities. This study evi-
denced that Siropins strongly inhibit the fecal proteases 
and mainly the elastolytic activities. Altogether, these 
results highlight the high potential of Siropins, and ser-
pin from the human gut microbiota, as a powerful thera-
peutic strategy to treat protease-mediated pathologies 
and mainly inflammatory bowel diseases.
Methods
Enzymes, reagents and substrates
Used human proteases: Human Neutrophil Elastase 
(HNE) and Human Proteinase 3 (PR3) were purchased 
from elastin products company (EPC, Inc). Porcine 
pancreatic elastase (PPE), bovine pancreatic trypsine 
(BPT), bovine pancreatic chymotrypsine (BPC) and sub-
tilisin Carlsberg (Sub) were obtained from Sigma. All 
substrates: Meosuc AAPV-pNA (Sigma) and MCA-RPK-
PVE-Nval-WRK(Dnp)-NH2 (Bachem) were used accord-
ing to the manufacturer’s instructions.
Fig. 7 Effects of Siropin on mice fecal proteases. Inhibition of total 
fecal proteolytic activity (a) and elastolytic activity (b) from DSS-
treated mice. Protease activities from mice drinking water alone 
were considered as 100%. Data are shown as mean ± SEM, *p < 0.05, 
**p < 0.01, ***p < 0.001 using Kruskal–Walls with Dunn’s post-test 
(n = 8 in each group)
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Bacterial strains, plasmids and media
Eubacterium siraeaum DSM 15702 strain was grown 
under anaerobic conditions in Medium 110 with 15% 
rumen fluid. Escherichia coli BL21 (DE3) were used in 
this study as host strain. Culture of different E. coli strains 
was done in Luria–Bertani (LB) medium. These media 
were supplemented, when necessary, with ampicillin 
(50  µg/ml), kanamycin (25  µg/ml) and IPTG (isopropyl 
β-d-thiogalactopyranoside) at 240  µg/ml. The pDONR-
221 and pDEST-17 plasmids (Promega) were used as 
entry and expression vectors respectively.
DNA manipulation and PCR
Chromosomal DNA was isolated from E. siraeum DSM 
15702 using the Wizard® Genomic DNA Purification kit 
(Promega). Preparation of plasmid DNA and separation 
of fragments by agarose gel electrophoresis were per-
formed as described by Sambrook et al. [38]. To amplify 
the genes encoding for Siropins, we used gene-specific 
and universal primer pairs in a 1∶4 ratio to generate the 
attachment binding sites (underlined) attb1 and attb2 in 
the final constructs. Based on the E. siraeum complete 
genomic sequence available in the NCBI Databank (ID: 
FP929044.1), we designed the specific oligonucleotide 
sequences F-SP1 5′GTACAAAAAAGCAGGCTTCAC 
AGGCATCAAAGCCGCAAGCC3′ and R-SP1 5′CAAG 
AAAGCTGGGTCTCATATACCTGTATACACGCC3′ 
for Siropin 1 gene amplification and both of F-SP2 5′GTAC 
A A A A A AG C AG G C T TC A A A AGA AGA AT T T T 
ATCAGCA3′ and R-SP2 5′CAAGAAAGCTGGGTCTT 
ATACGCCTGTATATATGCC3′ were used to amplify 
the Siropin 2 gene. Furthermore, F-33 5′GGGGACAAG 
TTTGTACAAAAAAGCAGGCTTC3′ and R-20 5′GGGG 
ACCACTTTGTACAAGAAAGCTGGGTC3′ were used 
in this study as universal primers. Polymerase chain reac-
tions were performed using Gene Amp® PCR System 
9700 (Applied Biosystems). The amplification reaction 
contained Takara DNA polymerase amplification buffer, 
20  pmol of each primer, 50  ng of DNA template, and 5 
units of Takara DNA polymerase (TaKaRa). PCR cycling 
parameters were: 94  °C for 5 min, followed by 25 cycles 
of 94 °C for 30 s, 55 °C for 60 s, and 72 °C for 120 s. PCR 
product was purified using QIAquick Gel Extraction Kit 
(Qiagen®) by following the manufacturer’s instructions. 
The purified fragments were used to be cloned into the 
Gateway plasmid pDONR-221 and therefore subcloned 
in the pDEST-17 expression vector by homologous 
recombination using the BP and LR clonase enzymes 
respectively (Invitrogen®). After transformation in com-
petent E. coli BL21 strain, numerous recombinant clones 
were obtained in case of each gene. Therefore sequence 
of two recombinant clones harboring the Siropins 1 
or 2 genes under the control of the T7 promoter with 
six histidines at the N-terminus of the protein, were 
confirmed.
Siropins expression and purification
Recombinant E. coli strains were grown as indicated 
above until the culture reached an OD600 of 0.6, and the 
culture was induced for 3 h using IPTG (240 μg/ml) fol-
lowed by harvesting of the cells by centrifugation (8000 g, 
for 15 min at 4  °C). Pellets were resuspended in 20 mM 
Tris–HCl buffer, pH 8.0 containing 500 mM NaCl. The 
cell suspensions (20 ml/pellet from 1 L of culture) were 
incubated for 1 h on ice in the presence of 10 mM MgCl2 
and 200 U benzonase (Novagen®). Cell disruption was 
done by sonication at 4 °C for 1 min (three cycles of 10 s 
pulses at amplitude of 40%) using a Vibra-CellTM 72408 
Sonicator and cell debris was removed by centrifugation 
(16,000g, for 30 min at 4 °C). Purification was performed 
by affinity chromatography using a 1 ml HiTrap chelating 
HP column (GE Healthcare) charged with Ni2+ ions on 
the ÄKTA Purifier FPLC system (Amersham Pharmacia 
Biotech) and equilibrated with 20 mM Tris–HCl pH 8.0 
buffer supplemented with 500 mM NaCl. Proteins were 
eluted using linear imidazole gradient ranging from 0 to 
500  mM. The fractions containing serpins activity were 
pooled and protein purification was achieved by size 
exclusion chromatography using Superdex S-200 10/300 
GL column (GE Healthcare). Proteins elution was done 
through an isocratic gradient with a flow rate of 0.3 ml/
min in the same buffer.
Protein analysis, amino acid sequence alignment 
and homology modeling
Protein concentration was determined by measuring 
the UV absorption at 280  nm using a Nanodrop device 
(Thermos Fisher Scientific). The protein samples were 
separated in 12% SDS-PAGE according to the Laemmli 
method [39], and bands were visualized by Coomassie 
brilliant blue R-250 (Bio-Rad) staining. The estimated 
molecular mass of purified Siropins was confirmed by the 
size exclusion chromatography. Correspondence of puri-
fied proteins to Siropins was confirmed by mass spec-
trometry and western blotting approaches.
Purified Siropins were analyzed by SDS-PAGE and then 
electrotransferred to nitrocellulose membranes (Hybond-
ECL, Amersham Biosciences) which were blocked in 
phosphate-buffered saline solution containing 0.05% 
Tween 20 (v/v) and 5% defatted milk powder (wt/vol) at 
4 °C during 1 h. Subsequently, blots were incubated with 
primary antibody (with 1/10,000 dilution of mouse anti-
polyHistidine monoclonal antibody, Sigma) at room tem-
perature for 1 h. Treated membranes were washed three 
times with the phosphate-buffered saline solution and 
incubated with goat anti-mouse HRP (Bio-Rad) during 
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1  h. Blot signals were detected using chemiluminescent 
substrate and ChemiDoc™ MP System (Bio-Rad).
The multiple alignment of the Serpin amino-acid 
sequence was done using the program ClustalW [40] and 
the figure rendering was done using the ESPript sequence 
analysis server [41]. The 3D homology model of Siropin 
1 and 2 was generated using the Geno3D server, and 
images were rendered by using VIEWERLITE™ 5.0.
Enzyme inhibition assays
All reactions were assayed in 20 mM tris–HCl, 500 mM 
NaCl, pH 8.0 buffer. All substrates were suspended in 
DMSO and stored at −80  °C and used in the final con-
centration of 200  µM for MeOSuc-AAPV-pNA and 
10  µM for MCA-RPKPVE-Nval-WRK(Dnp)-NH2. Reac-
tion mixture is composed of each serine protease with 
equimolar concentration of Siropin in the appropriate 
buffer and then incubated during 30  min. Inhibition is 
measured by addition of the chromogenic or fluorogenic 
substrates in a final volume of 100  µl in 96-well plates 
with clear or black bottom, respectively. Residual activ-
ity was determined during 20 min at 37 °C using a plate 
reader (Synergy™ 2 Multi-Mode Microplate Reader, 
BioTek®) for pNA substrates (absorbance at 405 nm) and 
(Dnp)-NH2 (excitation 360  nm, emission 460  nm). The 
final concentration of enzyme was 0.2, 0.3 and 1 µM for 
HNE, PR3 and PPE, respectively. Concentration of 50 nM 
was used for subtilisin (Sub), bovine pancreatic trypsin 
(BPT) and bovine pancreatic chymotrypsin (BPC).
Stoichiometry of inhibition
Stoichiometry of inhibition was determined by varying 
the amount of Siropins with a concentration of 200 nM 
for HNE and 300  nM for PR3. In fact, proteases and 
Siropins were gently mixed yielding to molar ratios of 
protease/inhibitor ranging from 0 to 10 during 5 min at 
37  °C. Therefore, substrate was then added and activ-
ity was assessed for 30  min by measuring absorbance 
at 405  nM. Fractional activity (velocity of the inhibited 
enzyme reaction/velocity of the non inhibited enzyme 
reaction) was subsequently calculated and plotted to the 
concentration ratio of the inhibitor to enzyme ([I0/E0]). 
The stoichiometry of inhibition was determined by linear 
regression as the x-intercept.
Determination of the P1–P1′ site of siropins and mass 
spectrometry analysis
The RCL cleavage site was determined by mixing Siro-
pin (40 µM) with HNE or PR3 in a total volume of 10 µl. 
Final enzyme/inhibitor ratio was 3 for HNE and 1 for 
PR3. After incubation for 5  min at 25  °C, the reaction 
was stopped by addition of 20  µl of boiling SDS-PAGE 
sample buffer followed by incubation for 5 min at 100 °C. 
Samples were then subjected to electrophoresis under 
reducing conditions according to the Laemmli method 
[39]. Subsequently, Protein bands of the Coomassie-
stained gel were excised and subjected to mass spec-
troscopy. The gel pieces were washed, reduced using 
DTT and alkylated with iodacetamide. 20–30 µl of 3 M 
HCl was then added and the dehydrated gel pieces were 
microwaved for 10  min at 900  W. The supernatant was 
removed and desalted directly on Oasis HLB Elution 
Plate (Waters). Samples were eluted in 50  μl, dried in a 
speed vacuum centrifuge and dissolved in 10 μl of recon-
stitution buffer (96:4 water/acetonitrile and 0.1% formic 
acid) and analyzed by LC–MS/MS. For this analysis, pep-
tides were separated using the nanoAcquity UPLC system 
(Waters) fitted with a trapping (nanoAcquity Symme-
try C18, 5  μm, 180  μm  ×  20  mm) and analytical col-
umn (nanoAcquity BEH C18, 1.7 μm, 75 μm × 200 mm) 
coupled directly to an linear trap quadropole (LTQ) 
OrbitrapVelos (Thermo Fisher Scientific) with a Prox-
eonnanospray source. The peptides were introduced into 
the mass spectrometer (OrbitrapVelos Pro, Thermo) and 
a spray of 2.2 kV was applied. Peptides analysis was per-
formed using MaxQuant Software (version 1.0.13.13). 
The data were searched against a species-specific (E. sir-
aeum) Uniprot database with a list of common contami-
nants appended.
Temperature, pH and stability profiles
The effect of temperature on the serpin activity was 
determined by incubating of each purified Siropin for 
30 min at various temperatures ranging from 4 to 90 °C 
and then the measurement of the residual inhibition 
was monitored. The Siropins pH profiles were obtained 
at different pH values between 2 and 10 (using 20  mM 
Tris–HCl, 500 mM NaCl). The stability as a function of 
temperature and pH was carried out by incubating each 
Siropin at different temperature and pH during different 
period and measuring residual activity.
Kinetic characterization of siropins
Kinetics of HNE and PR3 inhibition by Siropins were 
studied by the progress curve method [42, 43] under 
pseudo-first-order conditions, where the initial concen-
tration of Siropin were varied from 1 to tenfold greater 
than that of proteases. Initial reaction mixture contains 
substrate at final concentration of 200  µM and various 
amount of Siropins incubated at 37 °C for 10 min. There-
after 10 µl of HNE (200 nM) or PR3 (300 nM) were added 
to the mixture and the rate of the substrate hydrolysis 
was monitored at 405 nm for 20 min. The progress curves 
were fitted by non linear regression and the pseudo first 
order association rate constant, kobs, was calculated using 
the Eq. 1 [42, 43].
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where P is the product concentration, v0 is the substrate 
hydrolysis velocity and t is the reaction time. Determined 
kobs were plotted as a function of Siropin concentration. 
The apparent second order associate constant k′app was 
considered to be the slope of the fitted linear curve. Tak-
ing into account the competitive nature of inhibition by 
serpin, the second order association rates were then cor-
rected using the Eq. 2 [42, 43].
 
where [S] is substrate concentration and Km is the 
Michaelis–Menten constant determined from the 
Lineweaver–Burk plot. Km values were 114 µM for HNE 
and 270 µM for PR3.
Fecal protein extraction and inhibition analysis
Fecal samples collected from 57BL/6  J (6–8  weeks old) 
treated with phosphate buffer and DSS dissolved in 
drinking water (3%) during 7  days with free access to 
food and water. All procedures were performed accord-
ing to the European Community Rules and approved by 
the Animal Care Committee (C2E−45 COMETHEA) 
with authorization number A78-322-6.
Feces were homogenized in cooled 20  mM Tris–HCl, 
150  mM NaCl, pH8. Cells were subsequently lyzed by 
sonication at 4  °C for 1  min (3 cycles of 10  s pulses at 
amplitude of 40%) using a Vibra-CellTM 72408 Sonicator 
and cell debris was removed by centrifugation (15,000g, 
for 30  min at 4  °C). Recovered supernatants containing 
extracted proteins were then filtered (0.45 µm) and used 
for monitoring the fecal protease activity.
Reactions were performed in 20  mM Tris–HCl, 
150 mM NaCl, pH 8. Inhibition of total fecal proteolytic 
activity was performed in 1 ml reaction volume contain-
ing fecal proteins (0.1  mg/ml) with various amounts of 
Siropins and 100 µl of casein 1% (w/v). After incubation 
during 1 h at 37  °C, casein hydrolysis was stopped with 
500  µl of 20% (w/v) trichloracetic acid (sigma). Precipi-
tated proteins were removed by centrifugation (15,000g, 
15 min at 4  °C) and the residual enzymatic activity was 
measured in the clear supernatant at 280 nm.
The effect of Siropin on elastolytic activities were 
measured in 100  µl reaction volume using MeOSuc-
AAPV-pNA as substrate. Each fecal sample (4  mg/ml) 
was incubated with different amount of Siropin and then 
incubated for 30  min at 25  °C. Subsequently, substrate 
(150 µM) was added to the mixture and the absorbance 
change was monitored at 405  nm over 30  min at 37  °C 
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